Translation of "surveillant d'atelier de reliure " (French → English) :

As a consequence, slaughterhouses, cutting plants and meat processing establishments located in protection and surveillance zones defined according to Directive 2002/60/EC are restricted in the production, processing and distribution of pig meat, pig meat preparations, pig meat products and any other products consisting of or containing pig meat.

Without prejudice to Articles 4, 5 and 6 and Articles 11, 12 and 13 of this Decision, and by way of derogation from the prohibition provided in Article 3(3)(a) of Directive 2002/99/EC, the Member States concerned may authorise the dispatch of pig meat, pig meat preparations, pig meat products and any other products consisting of or containing pig meat from slaughterhouses, cutting plants and meat processing establishments which are located in protection and surveillance zones as laid down by Directive 2002/60/EC, provided that such products:

Derogation for slaughterhouses, cutting plants and meat processing establishments located in protection and surveillance zones

Meanwhile, the Library’s bindery created 3,345 bound volumes of parliamentary debates, journals and related collection items, and conserved more than 200 items of continuing value from Library collections, including several unique maps.

Indeed, Health Canada hosted in March a national workshop to look at coordination of surveillance for chemical contaminants in food, which would include the residues from veterinary drugs, pesticides and that kind of thing.

(Return tabled) Question No. 1123 Ms. Kirsty Duncan: With respect to the government’s position on chronic cerebrospinal venous insufficiency (CCSVI): (a) does the government track clinical trials on CCSVI currently being undertaken by other countries and, if yes, what are all clinical trials, identified by phase, currently being undertaken worldwide, (i) which countries are undertaking Phase lll trials; (b) does the government question whether CCSVI exists and, if yes, (i) why does the government not question whether treating CCSVI actually improves quality of life for Canadians with multiple sclerosis (MS); (c) how many cases of " maj ...[+++]or complications associated with venous angioplasty" have occurred in Canada and, if it is not possible to give this number, why, (i) what are identified complications to CCSVI and, for each complication, how many cases versus the number of procedures undertaken have occurred; (d) what are all procedures that have been performed on veins in Canada, including, procedures for Budd-Chiari syndrome and May-Thurner syndrome; (e) what is the government's position on ballooning veins and why does it consider that ballooning veins even once could be unsafe on fragile veins, even though participants involved in the proposed clinical trial will experience two procedures-one real, one simulated-in a one-year period; (f) is the government consulting with Canadians with MS, if so, (i) provide a list of all CCSVI groups the Minister of Health has met with along with the dates of the meetings, (ii) provide a list of all MS groups the Minister of Health has met with along with the dates of the meetings, (iii) provide the number of Canadians with MS the Minister of Health has met and the dates of all meetings, and if the government is not consulting, (iv) why not; (g) how does inviting the investigators of the seven MS-funded CCSVI studies to participate in the consensus workshop on ultrasound imaging meet CIHR's conflict of interest g ...